Helsinki-based healthtech startup CurifyLabs has secured €6.7 million in fresh funding to scale its automated platform for producing patient-specific compounded medications.
The round was led by Finnish growth investment platform Springvest, with a €1 million deeptech loan from Business Finland.
The company, which now has a total funding of €17.6 million, will use the capital to expand into high-volume markets and continue scaling operations across Finland, the US, and Germany.
A smarter way to make personalised drugs
Traditional compounded medications—custom formulations prepared when standard drugs don’t meet individual patient needs—are time-consuming and inconsistent. CurifyLabs aims to change that with its fully automated “Compounding System Solution.”
Using a desktop robot dubbed the Pharma Printer, the platform combines proprietary excipient bases, active ingredients, and cloud-based software to create tailored pills or liquids. The system guides pharmacists with step-by-step instructions and built-in quality control, significantly reducing manual labour and human error.
Co-founder and CEO Charlotta Topelius explained, “Even with trained pharmacists and modern tools, compounding is still outdated and error-prone. We’re building the tools to ensure patients—like infants with cancer—get the right medication, at the right dose, every time.”
Advertisement
Global expansion and new robotics project
As demand for customised medicines grows, CurifyLabs is positioning itself for rapid scale-up. The global compounding market is currently valued at €15 billion and expanding at over 5% annually.
In tandem with the funding announcement, the company also launched RoboPharma, a €5.6 million EU-backed initiative to decentralise pharmaceutical manufacturing using AI and robotics. The goal is to equip hospitals and pharmacies with local production capabilities, ensuring medicine access even during supply chain disruptions.
Aki Soudunsaari, CEO of Springvest, added, “This is a game-changing solution that addresses a huge gap in the pharmaceutical market while improving safety for vulnerable patients like children. The US market presents massive growth potential, and we’re excited to back CurifyLabs as it scales.”
